DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
Year: 2015
Type: article
Study design: Observational Study
Abstract: DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype Somatic mutations in JAK2, CALR and MPL are found in the majority of myeloproliferative neoplasms (MPN) but many patients also harbor somatic mutations in epigenetic regulators of DNA methylation (TET2, DNMT3A and IDH1/2) or chromatin structure (ASXL1 and EZH2).In MPN patients, mutations in TET2, ASXL1 and EZH2 occur either prior to or following the acquisition of JAK2 V617F 1 and, recently, the order of mutation acquisition for JAK2 V617F and TET2 has been shown to influence hematopoietic stem/progenitor cell biology and clinical presentation.2 DNMT3A is the next most frequently mutated gene in MPN after TET2, affecting 7-10% of patients.[3][4][5] However in contrast to other mutations, DNMT3A mutations (DNMT3A mut ) have only been reported early in myeloid disease: prior to acquisition of JAK2 V617F or in a separate clone in MPN; 1,6 prior to NPM1 or FLT3 mutations in de novo acute myeloid leukemia; 7 and prior to transformation of MPN or myelodysplasia into acute myeloid leukemia.8 In this study we used clonal analysis of hematopoietic colonies from DNMT3A mut MPN patients to investigate timing of mutation acquisition, subclonal evolution, and the influence of mutation order.Thirteen DNMT3A mut MPN patients were identified in whom viable material was available for clonal analysis (Online Supplementary Table S1): nine JAK2 V617F -mutated and two MPL-mutated patients identified by exome-sequencing, one JAK2 exon12 -mutated patient identified by wholegenome sequencing, and one CALR-mutated patient identified by targeted gene screening.MPN diagnoses conformed to British Committee for Standards in Haematology.All samples were obtained following written informed consent and ethical approval.Peripheral blood mononuclear cells were cultured to obtain burstforming units-erythroid (BFU-E) as described previously, 2 and 2991 individual colonies (average of 230 colonies/patient) were genotyped by Sanger sequencing for mutations in DNMT3A, JAK2, CALR and MPL.DNMT3A mut occurred prior to acquisition of JAK2 V617F in four patients ('DNMT3A-first' patients, Figure 1A) as evidenced by single-mutant colonies harboring DNMT3A mut only and double-mutant colonies with DNMT3A mut and JAK2 V617F.Single-mutant colonies represented a substantial proportion of BFU-E (mean 58%, range 27%-86%), consistent with mutant allele fractions from granulocyte whole-exome sequencing, and indicating the presence of significant 'pre-JAK2' multi-lineage clonal hematopoiesis in these patients.These results accord with observations of clonal hematopoiesis in patients with essential thrombocythemia despite low allele burdens of JAK2 V617F , 9 and with reports of DNMT3A mut -associated clonal hematopoiesis in normal individuals.10,11 In three patients, DNMT3A mut and JAK2 V617F colonies were mutually exclusive ('biclonal' patients, Figure 1B).In such patients, the two mutations arose either in separate cells downstream of a shared ancestral clone or in clonally unrelated cells.DNMT3A mut and JAK2 V617F clones did not share any of the additional mutations identified by exome sequencing in the three biclonal patients (Figure 2 patients #25, #81, #27).Moreover, in one of the two female patients, DNMT3A mut and JAK2 V617F clones harbored different active X-chromosomes (Online Supplementary Figure S1).These data demonstrate that DNMT3A mut and JAK2 V617F clones in the same patient can represent clonally-unrelated expansions.
Source: Haematologica
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
Funders: Leukemia and Lymphoma Society, Wellcome Trust, Cancer Research UK, National Institute for Health and Care Research, Kay Kendall Leukaemia Fund, Leukaemia and Lymphoma Research, University of Cambridge, Medical Research Council, Cambridge Institute for Medical Research, University of Cambridge
OpenAlex ID: W2175028143
